Onkologie. 2019:13(4):167-172 | DOI: 10.36290/xon.2019.032

Current approaches to the radiotherapy of brain metastases from solid tumors

Tomáš Kazda1,2,3, Radek Lakomý4,5, Petr Pospíšil1,2, Ludmila Hynková1,2, Jiří Šána3,4,5, Pavel Fadrus6, Radim Jančálek7,8, Robert Bartoš9,10, Renata Belanová8,11, Ondřej Slabý3,4,5, Pavel Šlampa1,2
1 Klinika radiační onkologie, Masarykův onkologický ústav, Brno
2 Klinika radiační onkologie, Lékařská fakulta Masarykovy Univerzity, Brno
3 CEITEC – Středoevropský technologický institut, Masarykova Univerzita, Brno
4 Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno
5 Klinika komplexní onkologické péče, Lékařská fakulta Masarykovy Univerzity, Brno
6 Neurochirurgická klinika, Fakultní nemocnice Brno, Brno
7 Neurochirurgická klinika, Fakultní nemocnice u sv. Anny v Brně, Brno
8 Lékařská fakulta Masarykovy Univerzity, Brno
9 Neurochirurgická klinika University J. E. Purkyně, Masarykova nemocnice, KZ a. s., Ústí nad Labem
10 Anatomický ústav 1. LF UK, Praha
11 Oddělení radiologie, Masarykův onkologický ústav, Brno

Secondary brain tumors, brain metastases, develop in up to 30–40 % of all solid tumor cancer patients, with increasing incidence.
The aim of this review is to provide both basic as well as current information on up-to-date treatment options for patients with
brain metastases. The aim is, in accordance with the focus of the journal, to provide didactical and practical information on the
issue of radiotherapy of secondary brain tumors with an emphasis on their usefulness in daily clinical practice. Several large randomized
trials potentially affecting daily practice have recently been published and are discussed in this review.

Keywords: brain metastases, radiotherapy, stereotactic radiotherapy

Published: September 15, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kazda T, Lakomý R, Pospíšil P, Hynková L, Šána J, Fadrus P, et al.. Current approaches to the radiotherapy of brain metastases from solid tumors. Onkologie. 2019;13(4):167-172. doi: 10.36290/xon.2019.032.
Download citation

References

  1. Achrol AS, Rennert RC, Anders C, et al. Brain metastases. Nat Rev Dis Primers. 2019; 5(1): 5. Go to original source... Go to PubMed...
  2. Soffietti R, Abacioglu U, Baumertet B, et al. Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO). Neuro Oncol. 2017; 19(2): 162-174. Go to original source... Go to PubMed...
  3. Mehta MP, Aoyama H, Gondi V. The Changing Role of Whole-Brain Radiotherapy: Demise or Time for Selective Usage? JAMA Oncol. 2017; 3(8): 1021-1022. Go to original source... Go to PubMed...
  4. Kazda T, Pospíšil P, Doleželová H, et al. Whole brain radiotherapy: Consequences for personalized medicine. Rep Pract Oncol Radiother. 2013; 18(3): 133-138. Go to original source... Go to PubMed...
  5. Kazda T, Jancalek R, Pospisil P, et al. Why and how to spare the hippocampus during brain radiotherapy: the developing role of hippocampal avoidance in cranial radiotherapy. Radiat Oncol. 2014; 9: 139. Go to original source... Go to PubMed...
  6. Tsao MN, Xu W, Wong RK, et al. Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases. Cochrane Database Syst Rev. 2018; 1: CD003869. Go to original source... Go to PubMed...
  7. Mulvenna P, Nankivell M, Barton R, et al. Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial. Lancet. 2016; 388(10055): 2004-2014. Go to original source... Go to PubMed...
  8. Slotman B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. 2007; 357(7): 664-672. Go to original source... Go to PubMed...
  9. Gondi V, Tomé WA, Mehta MP. Why avoid the hippocampus? A comprehensive review. Radiother Oncol. 2010; 97(3): 370-376. Go to original source... Go to PubMed...
  10. Gondi V, Tolakanahalli R, Mehta MP, et al. Hippocampalsparing whole-brain radiotherapy: a "how-to" technique using helical tomotherapy and linear accelerator-based intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2010; 78(4): 1244-1252. Go to original source... Go to PubMed...
  11. Gondi V, Pugh SL, Tome WA, et al. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. J Clin Oncol. 2014; 32(34): 3810-3816. Go to original source... Go to PubMed...
  12. Kotecha R, Gondi V, Ahluwalia MS, et al. Recent advances in managing brain metastasis. F1000Res. 2018; 7: F1000 Faculty Rev-1772. Go to original source... Go to PubMed...
  13. Brown PD, Pugh S, Laack NN, et al. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro Oncol. 2013; 15(10): 1429-1437. Go to original source... Go to PubMed...
  14. Gondi V, Tome WA, Marsh J, et al. Estimated risk of perihippocampal disease progression after hippocampal avoidance during whole-brain radiotherapy: safety profile for RTOG 0933. Radiother Oncol. 2010; 95(3): 327-331. Go to original source... Go to PubMed...
  15. Brown PD, Jaeckle K, Ballman KV, et al. Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial. JAMA. 2016; 316(4): 401-409. Go to original source... Go to PubMed...
  16. Yamamoto M, Serizawa T, Shuto T, et al. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol. 2014; 15(4): 387-395. Go to original source... Go to PubMed...
  17. Yamamoto M, Serizawa T, Higuchi Y, et al. A Multi-institutional Prospective Observational Study of Stereotactic Radiosurgery for Patients With Multiple Brain Metastases (JLGK0901 Study Update): Irradiation-related Complications and Long-term Maintenance of Mini-Mental State Examination Scores. Int J Radiat Oncol Biol Phys. 2017; 99(1): 31-40. Go to original source... Go to PubMed...
  18. Patchell RA, Tibbs PA, Regine WF, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA. 1998; 280(17): 1485-1489. Go to original source... Go to PubMed...
  19. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990; 322(8): 494-500. Go to original source... Go to PubMed...
  20. Kocher M, Soffietti R, Abacioglu U, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol. 2011; 29(2): 134-41. Go to original source... Go to PubMed...
  21. Lakomy R, Hynkova L, Pospisil P, et al. Patterns of failure after brain metastases radiotherapy: reflections on the importance for treatment and clinical trials reporting. Neoplasma. 2017; 64(3): 329-337. Go to original source... Go to PubMed...
  22. Mahajan A, Ahmed S, McAleer MF, et al. Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017; 18(8): 1040-1048. Go to original source... Go to PubMed...
  23. Brown PD, Ballman KV, Cerhan JH, et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CECo3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017; 18(8): 1049-1060. Go to original source... Go to PubMed...




Oncology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.